AtriCure to Announce Fourth Quarter and Full Year 2020 Financial Results

Rhea-AI Summary

AtriCure, Inc. (Nasdaq: ATRC) will release its fourth quarter and full year 2020 financial results on February 23, 2021.

The company will host a conference call at 4:30 p.m. ET on the same day to discuss these results. Interested parties can join the call via phone or listen to a live audio webcast on AtriCure's corporate website. AtriCure specializes in innovative technologies for treating atrial fibrillation (Afib) and left atrial appendage (LAA) management, offering FDA-approved devices that lead the market.

Positive

• AtriCure's Isolator® Synergy™ Ablation System is FDA-approved for persistent Afib.
• AtriCure's AtriClip® products are the most widely sold LAA management devices globally.

Negative

• None.

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its fourth quarter and full year 2020 financial results on Tuesday, February 23, 2021.

AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, February 23, 2021 to discuss its fourth quarter and full year 2020 financial results. The call may be accessed through an operator by dialing (844) 884-9951 for domestic callers and (661) 378-9661 for international callers, using conference ID number 6352259. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure’s corporate website at ir.atricure.com. A replay of the webcast will be available for 90 days following the presentation.

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210202005111/en/

FAQ

When will AtriCure release its 2020 financial results?

AtriCure will release its financial results on February 23, 2021.

What time is AtriCure's conference call on February 23, 2021?

The conference call will be held at 4:30 p.m. Eastern Time.

How can I access the AtriCure conference call?

You can access it by dialing (844) 884-9951 for domestic callers or (661) 378-9661 for international callers, using conference ID number 6352259.

What innovations does AtriCure offer for atrial fibrillation?

AtriCure provides technologies for Afib treatment, including the Isolator® Synergy™ Ablation System and AtriClip® devices.